Cargando…

PCSK9-D374Y Suppresses Hepatocyte Migration through Downregulating Free Cholesterol Efflux Rate and Activity of Extracellular Signal-Regulated Kinase

Proprotein convertase subtilisin/kexin type 9 can mediate the intracellular lysosomal degradation of the low-density lipoprotein receptor protein in hepatocytes and decrease the liver's ability to scavenge low-density lipoprotein cholesterol from circulation, resulting in high levels of cholest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Lei, Cheng, Ying, Mu, Yulian, Li, Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842426/ https://www.ncbi.nlm.nih.gov/pubmed/36655117 http://dx.doi.org/10.1155/2023/6985808

Ejemplares similares

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9
por: Choi, Seungbum, et al.
Publicado: (2013)

Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
por: Ying, Qidi, et al.
Publicado: (2022)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Lupin Peptide T9 (GQEQSHQDEGVIVR) Modulates the Mutant PCSK9(D374Y) Pathway: in vitro Characterization of its Dual Hypocholesterolemic Behavior
por: Lammi, Carmen, et al.
Publicado: (2019)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

LXR Suppresses Inflammatory Gene Expression and Neutrophil Migration through cis-Repression and Cholesterol Efflux
por: Thomas, David G., et al.
Publicado: (2018)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Acanthaster planci Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
por: Kamaruddin, Nurjannatul Naim, et al.
Publicado: (2021)

PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
por: Päth, Günter, et al.
Publicado: (2022)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Macrophage Cholesterol Efflux Downregulation Is Not Associated with Abdominal Aortic Aneurysm (AAA) Progression
por: Canyelles, Marina, et al.
Publicado: (2020)

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
por: Kaya, Esra, et al.
Publicado: (2017)

Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia
por: Eroğlu, Zuhal, et al.
Publicado: (2018)

Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis
por: Murphy, Andrew J., et al.
Publicado: (2013)

Targeted cholesterol efflux
por: Fang, Longhou, et al.
Publicado: (2013)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network
por: Chae, Hee-Sung, et al.
Publicado: (2018)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol
por: Ioannou, George N., et al.
Publicado: (2021)

RAGE Suppresses ABCG1-Mediated Macrophage Cholesterol Efflux in Diabetes
por: Daffu, Gurdip, et al.
Publicado: (2015)

9-cis β-Carotene Increased Cholesterol Efflux to HDL in Macrophages
por: Bechor, Sapir, et al.
Publicado: (2016)

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
por: Papotti, Bianca, et al.
Publicado: (2022)

Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes
por: Ning, Liuxin, et al.
Publicado: (2023)

A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo
por: Suchowerska, Alexandra K., et al.
Publicado: (2022)

Dynamic Regulation of Extracellular Superoxide Production by the Coccolithophore Emiliania huxleyi (CCMP 374)
por: Plummer, Sydney, et al.
Publicado: (2019)

Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics
por: Maslyanko, Maria, et al.
Publicado: (2021)

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion
por: Chen, Xiao-Wei, et al.
Publicado: (2013)

Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms
por: van Asch, Barbara, et al.
Publicado: (2021)

Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review
por: Gianazza, Erica, et al.
Publicado: (2023)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte
por: Udden, SM Nashir, et al.
Publicado: (2019)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Molecular Mechanisms of Cellular Cholesterol Efflux
por: Phillips, Michael C.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1f8u2h5vr23mvqip8jb28msa16